The importance of serum biglycan levels as a fibrosis marker in patients with chronic hepatitis B

Background Liver biopsy is recommended in the majority of patients with chronic viral hepatitis for fibrosis evaluation. Because of the potential risks of liver biopsy, many studies related to non‐invasive biomarkers of hepatic fibrosis have been performed. We aimed to assess the diagnostic value of...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical laboratory analysis 2017-09, Vol.31 (5), p.e22109-n/a
Main Authors: Ciftciler, Rafiye, Ozenirler, Seren, Yucel, Aysegul Atak, Cengiz, Mustafa, Erkan, Gulbanu, Buyukdemirci, Erkan, Sönmez, Cemile, Esendaglı, Guldal Yılmaz
Format: Article
Language:English
Subjects:
Adult
biglycan
Biglycan - blood
Biomarkers - blood
Biopsy
chronic hepatitis B
Enzyme-linked immunosorbent assay
Female
Fibrosis
Hepatitis
Hepatitis B
Hepatitis B, Chronic - blood
Hepatitis B, Chronic - diagnosis
Hepatitis B, Chronic - epidemiology
Humans
Interferon
Liver
liver biopsy
Liver Cirrhosis - blood
Liver Cirrhosis - diagnosis
Liver Cirrhosis - epidemiology
liver fibrosis
Male
Middle Aged
non‐invasive marker
Prospective Studies
ROC Curve
Statistical analysis
Statistics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Liver biopsy is recommended in the majority of patients with chronic viral hepatitis for fibrosis evaluation. Because of the potential risks of liver biopsy, many studies related to non‐invasive biomarkers of hepatic fibrosis have been performed. We aimed to assess the diagnostic value of serum biglycan as a non‐invasive fibrosis marker in chronic hepatitis B patients. Methods This study included 120 patients with biopsy‐proven hepatitis B patients and 60 healthy controls. Fibrosis stage and necroinflammatory activity were assessed in liver biopsy specimens. Biglycan level was measured using an ELISA assay. Results Serum biglycan levels of chronic hepatitis B patients were found to be significantly higher than those of healthy controls (337.3±363.0 pg/mL vs 189.1±61.9 pg/mL, respectively, P
ISSN:0887-8013
1098-2825
DOI:10.1002/jcla.22109